Variability in calculating non-HDL atherogenic lipoprotein in reference to atherogenic index in type 2 diabetes

Atherogenic lipoprotein particles in atherosclerosis.

The importance of low-density lipoprotein (LDL) cholesterol in the development of atherosclerosis has long been recognized, and LDL cholesterol remains the primary target of therapy for the prevention of coronary heart disease. Nevertheless, increasing research attention over the past decade has been devoted to the heterogeneity of LDL particles and the atherogenicity of lipids and lipoproteins...

Anti-atherogenic effects of fibrates in type 2 diabetes

Type 2 diabetes is an increasing cause of premature coronary heart disease. Several trials with lipid-modifying therapy have included sufficient numbers of diabetics to indicate that treatment of diabetic dyslipidaemia with either fibrates or statins reduces the risk of future coronary events in such patients. However, until recently no reported study had been designed specifically to investiga...

Lipoprotein (a) and atherogenic indices in Sudanese patients with type 2 diabetes.

BACKGROUND & AIMS Type 2 diabetes is associated with significant cardiac morbidity and mortality with a more than threefold increased risk of coronary artery disease (CAD). We aimed to assess the serum concentrations of lipoprotein (a) and lipid profile indexes as predictors for CAD in Sudanese type 2 diabetics compared to healthy subjects. MATERIALS & METHODS This case-control study was cond...

dyslipidemia in type 2 diabetes mellitus: more atherogenic lipid profile in women

previous studies have shown that diabetes mellitus (dm) increases the risk of cardiovascular disease in women to a greater extent than in men. it seems that dm may alter lipid profiles more adversely in women compared to men. in this study we evaluated serum lipoprotein differences in type 2 diabetic men and women. the study included 350 type 2 diabetic patients (100 men and 250 women), aged 19...

A Non-Atherogenic and Atherogenic Lipoprotein Profile in Individuals with Dyslipoproteinemia